Raymond James Downgrades Neogenomics (NEO) to Market Perform
- Tech stocks push S&P 500 to record close, buoy Nasdaq
- U.S. Calls for Pause of J&J (JNJ) Vaccine After Clotting Cases, Including One Death
- Coinbase (COIN) direct listing IPO reference price set at $250
- Biggest SPAC Deal Ever: Grab To Go Public in a $40 Billion Merger With Altimeter (AGC), Backed by Fidelity and BlackRock
- Oil rises after robust China data but J&J vaccine pause weighs
Raymond James analyst Andrew Cooper downgraded Neogenomics (NASDAQ: NEO) from Outperform to Market Perform.
Shares of Neogenomics closed at $54.34 yesterday.
You May Also Be Interested In
- NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference
- Truist Securities Downgrades Cadence BanCorp (CADE) to Hold
- UPDATE: BofA Securities Downgrades Lucira Health Inc. (LHDX) to Underperform
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!